HSV-MARKERS AND THE EPIDEMIOLOGY OF CERVICAL CANCER

HSV 标记物和宫颈癌的流行病学

• 批准号: 3173427
• 负责人: LEWIS I PIZER
• 金额: $ 6.73万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1983
• 资助国家: 美国
• 起止时间: 1983-07-01 至 1986-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3173427
• 关键词: Herpes simplex disease; autoradiography; cervix neoplasms; genetic manipulation; genetic markers; genital herpes; herpes simplex virus 1; herpes simplex virus 2; human tissue; immunologic techniques; leukocyte activation /transformation; microorganism immunology; molecular cloning; neoplasm /cancer epidemiology; radiotracer; virus DNA; virus antigen; virus classification

The experimental program described in this proposal is designed to quantitate markers of Herpes simplex virus (HSV) infection in a human population already participating in an epidemiological study of cervical cancer. The patients and control groups are individuals involved in the study entitled "Case-control study of cervical cancer". The patients and control groups are individuals involved in the study entitled "Case-control study of invasive cervical cancer", funded by the National Cancer Institute, at present underway at the University of Colorado School of Medicine. As a collaborative endeavor, we plan to utilize blood from these individuals to assay for evidence of Herpes simplex virus infection and determine the extent of their immune responsiveness to viral antigens. The specific aims are: 1) To quantitate lymphocyte proliferation in response to inactivated HSV-1 and HSV-2 virus and a type specific glycoprotein (gC); 2) To examine circulating lymphocytes for the presence of viral DNA, measure the amount of DNA, and by use of specific probes establish whether the virus is type 1 or type 2; 3) To determine by an enzyme linked immunoassay, the serum antibody levels against total herpes virus antigens and the type specific glycoprotein gC; and 4) To utilize these techniques in persons with known HSV infections, and to incorporate these techniques into an on-going study of cervical cancer cases and controls. The quantitative data generated by the laboratory will first be developed using known HSV infected cell lines in in vitro experiments. Next, white cell material will be obtained from persons known to be infected with HSV-1 and HSV-2 from the sexually transmitted diseases clinic of Denver Health and Hospitals. This will serve to validate the findings, and help establish the sensitivity and specificity of the procedures. Next, and the principal focus of the collaborative portion of this proposal, white cell samples will be analyzed from persons already participating in the case-control study of cervical cancer. This will allow examination of the laboratory information on HSV experience simultaneously with epidemiologic information relevant to other potential etiologic and confounding factors, such as smoking, nutritional status, sexual and infectious disease history, and contraceptive and hormone useage patterns.

本提案中描述的实验计划旨在 定量人类单纯疱疹病毒 (HSV) 感染标记物 已经参与宫颈癌流行病学研究的人群 癌症。 患者和对照组是参与该研究的个人 研究题为“宫颈癌病例对照研究”。 患者和 对照组是参与题为“病例对照”研究的个人 浸润性宫颈癌研究”，由国家癌症中心资助 研究所目前正在科罗拉多大学学院进行 药品。 作为一项合作努力，我们计划利用这些血液 个人检测单纯疱疹病毒感染的证据和 确定他们对病毒抗原的免疫反应程度。 这 具体目标是： 1) 定量响应中的淋巴细胞增殖 灭活的 HSV-1 和 HSV-2 病毒以及类型特异性糖蛋白 (gC)； 2) 检查循环淋巴细胞中是否存在病毒 DNA， 测量 DNA 的量，并通过使用特定探针确定是否 病毒为 1 型或 2 型； 3) 通过酶联法测定 免疫测定，针对疱疹病毒总抗原的血清抗体水平 和类型特异性糖蛋白gC； 4）利用这些技术 已知 HSV 感染者，并结合这些技术 正在进行的宫颈癌病例和对照研究。 这 实验室生成的定量数据将首先使用 体外实验中已知HSV感染的细胞系。 接下来是白细胞 材料将从已知感染 HSV-1 的人处获得，并且 HSV-2，来自丹佛健康和性传播疾病诊所 医院。 这将有助于验证研究结果，并帮助建立 程序的敏感性和特异性。 接下来是校长 该提案的协作部分的重点是白细胞样本 将从已经参与病例控制的人员中进行分析 宫颈癌的研究。 这将允许实验室检查 HSV 经历信息与流行病学信息同时进行 与其他潜在的病因和混杂因素相关，例如 吸烟、营养状况、性病和传染病史，以及 避孕药具和激素的使用模式。